Professur für Translationale Frauenheilkunde und Geburtshilfe

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program (2021) Muller V, Banys-Paluchowski M, Friedl TWP, Fasching P, Schneeweiss A, Hartkopf A, Wallwiener D, et al. Journal article Global Phase 3 Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy (2021) Rugo H, Chow LWC, Cortes J, Fasching P, He XB, Hsu P, Huang CS, et al. Conference contribution Phase II neoadjuvant study of GDC-9545+palbociclib (palbo) vs anastrozole (A) plus palbo in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC) (2021) Hurvitz SA, Fasching P, Park YH, Quiroga V, Crnjevic TB, Fresco R, Lopez-Valverde V, et al. Conference contribution ABEMACARE: Abemaciclib in combination with endocrine therapy as first line therapy in metastatic breast cancer patients with symptomatic visceral metastases or high tumor burden (2021) Kotzur F, Bidner H, Bronger H, Egert S, Fasching P, Fischer D, Kehl V, et al. Conference contribution Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry—comparison of three different GPA prognostic scores (2021) Riecke K, Müller V, Weide R, Schmidt M, Park‐simon TW, Möbus V, Mundhenke C, et al. Journal article Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial (2021) Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, et al. Journal article Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2-Advanced Breast Cancer (2021) Fasching P, Delea TE, Lu YS, De Boer R, Hurvitz SA, Moynahan A, Chandiwana D, et al. Journal article Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer (2021) Schneeweiss A, Michel LL, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, et al. Journal article Erratum: AGO Recommendations for the Surgical Therapy of the Axilla after Neoadjuvant Chemotherapy: 2021 Update (Geburtshilfe Frauenheilkd (2021) 81:10 (1112-1120) DOI: 10.1055/a-1499-8431) (2021) Friedrich M, Kühn T, Janni W, Müller V, Banys-Paluchowski M, Kolberg-Liedtke C, Jackisch C, et al. Journal article, Erratum Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial (2021) Llop-Guevara A, Loibl S, Villacampa G, Vladimirova V, Schneeweiss A, Karn T, Zahm DM, et al. Journal article